for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GlaxoSmithKline Pharmaceuticals Limited

GLAX.NS

Latest Trade

1,438.70INR

Change

-1.40(-0.10%)

Volume

36,237

Today's Range

1,433.00

 - 

1,468.95

52 Week Range

1,130.00

 - 

1,520.00

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
1,440.10
Open
1,446.00
Volume
36,237
3M AVG Volume
1.02
Today's High
1,468.95
Today's Low
1,433.00
52 Week High
1,520.00
52 Week Low
1,130.00
Shares Out (MIL)
169.41
Market Cap (MIL)
243,961.60
Forward P/E
49.49
Dividend (Yield %)
1.39

Next Event

Q3 2020 GlaxoSmithKline Pharmaceuticals Ltd Earnings Release

Latest Developments

More

Glaxosmithkline Pharmaceuticals Recalls Zinetac Tablets Manufactured In India

India's Glaxosmithkline Pharma Sells Company Land In Western India

Glaxosmithkline Pharmaceuticals Sells Land to Oberoi Realty

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited is a pharmaceutical company. The Company and its subsidiary are engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company develops a range of products in approximately three areas, including pharmaceuticals, vaccines and consumer healthcare. The Company's product portfolio includes prescription medicines and vaccines. The Company's prescription medicines range across therapeutic areas, and it also offers a range of vaccines for prevention of life-threatening diseases, such as pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough, small pox and influenza. It provides healthcare solutions to patients, with a range of prescription medicines across areas covering anti-infectives, dermatology, gynecology, diabetes, oncology, cardiovascular disease and respiratory diseases. The Company's manufacturing unit is located at Nashik, and its clinical development center is located in Bangalore.

Industry

Biotechnology & Drugs

Contact Info

Dr Annie Besant Road, Worli

+91.22.24959595

http://india-pharma.gsk.com/

Executive Leadership

Deepak S. Parekh

Non-Executive Chairman of the Board

Puja Thakur

Chief Financial Officer, Whole Time Director

D. Bartaria

Executive Vice President– Pharmaceuticals

H. Buch

Executive Vice President - Pharmaceuticals

Ajay A. Nadkarni

Compliance Officer, Company Secretary, General Manager - Administration

Key Stats

3.67 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2017

29.3K

2018

28.7K

2019

31.3K

2020(E)

35.1K
EPS (INR)

2017

17.200

2018

19.655

2019

24.600

2020(E)

29.098
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-India's Glaxosmithkline Pharmaceuticals Dec Qtr Profit Rises

* DEC QUARTER PROFIT 896.9 MILLION RUPEES VERSUS PROFIT 529.5 MILLION RUPEES YEAR AGO

BRIEF-Glaxosmithkline Pharmaceuticals ‍appoints Puja Thakur as CFO​

* Says appointed Puja Thakur as whole-time director and CFO Source text: http://bit.ly/2gDubM1 Further company coverage:

BRIEF-India's Glaxosmithkline Pharmaceuticals Sept-qtr profit up 32 pct

* Sept quarter profit 1.30 billion rupees versus profit of 988.5 million rupees last year

BRIEF-India's Glaxosmithkline Pharmaceuticals June-qtr profit down about 63 pct

* June quarter profit 264.2 million rupees versus profit of 722.7 million rupees last year

BRIEF-India's Glaxosmithkline Pharma March-qtr profit rises about 6 pct

* Says recommended a dividend of 300 pct on equity share capital

BRIEF-Glaxosmithkline Pharma says promoter Glaxosmithkline Pte raises stake in co by 3.77 pct

* Says promoter Glaxosmithkline Pte Ltd raises stake in co by 3.77 percent to 28.10 percent Source text for Eikon: Further company coverage:

BRIEF-GlaxoSmithKline Pharmaceuticals Sept qtr profit up about 3.5 pct

* GlaxoSmithKline Pharmaceuticals Ltd - sept quarter net profit 988.5 million rupees

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up